These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31213466)

  • 41. John L. McNulty (1955-2023).
    Bryant WT; Miles SR; Arbisi PA; Ben-Porath YS; Harkness AR
    Am Psychol; 2024; 79(5):784. PubMed ID: 38619482
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fifty years of systemic therapy for breast cancer: from one size fits all to tailored therapy.
    Burstein HJ
    Am Soc Clin Oncol Educ Book; 2014; ():e1-3. PubMed ID: 24857085
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting the EGFR pathway for cancer therapy.
    Johnston JB; Navaratnam S; Pitz MW; Maniate JM; Wiechec E; Baust H; Gingerich J; Skliris GP; Murphy LC; Los M
    Curr Med Chem; 2006; 13(29):3483-92. PubMed ID: 17168718
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Celebrating Professor Britton Chance (1913-2010), a founding father of redox sciences.
    Ohnishi T; Zweier JL
    Antioxid Redox Signal; 2011 Dec; 15(11):2815-7. PubMed ID: 21563984
    [TBL] [Abstract][Full Text] [Related]  

  • 45. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
    Dobrić I
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A tribute to Richard F. Edlich, MD, PhD.
    Lineaweaver WC
    J Environ Pathol Toxicol Oncol; 2010; 29(4):267-70. PubMed ID: 21284592
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A tribute to the life and career of Holbrook Kohrt.
    Marabelle A; Houot R
    Ann Oncol; 2016 Jul; 27(7):1183-4. PubMed ID: 27166293
    [No Abstract]   [Full Text] [Related]  

  • 48. Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy.
    Habban Akhter M; Sateesh Madhav N; Ahmad J
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1188-1198. PubMed ID: 29991287
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human tumor stem cells, the petri dish and the patient. A tribute to Sydney E. Salmon.
    Bataille R; Drouin E
    Vesalius; 2011 Jun; 17(1):42-4. PubMed ID: 22043602
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody therapeutics in cancer.
    Sliwkowski MX; Mellman I
    Science; 2013 Sep; 341(6151):1192-8. PubMed ID: 24031011
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Edward E. Cornwell III, MD, FACS, FCCM.
    J Natl Med Assoc; 2008 Apr; 100(4):357-8. PubMed ID: 18481473
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Donald J. Reis, MD: research mentor extraordinaire.
    Hoff JT
    Cell Mol Neurobiol; 2003 Oct; 23(4-5):457-61. PubMed ID: 14514007
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CCR 20th Anniversary commentary: in search of cetuximab's first indication-combination therapy with irinotecan in colorectal cancer.
    Hicklin DJ
    Clin Cancer Res; 2015 Apr; 21(7):1505-7. PubMed ID: 25833307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
    Gui T; Shen K
    Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Redox pioneer: Professor Arne Holmgren.
    Arnér ES
    Antioxid Redox Signal; 2011 Aug; 15(3):845-51. PubMed ID: 21473701
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Professor Hassan K. Awwad; The Father of Radiation Oncology and Radiobiology in Egypt and the Arab World, His Good Deeds Last Forever and Inspire us for the Future.
    Zaghloul MS; El-Badawi SA; Abd Elbaky H
    J Egypt Natl Canc Inst; 2007 Mar; 19(1):1-2. PubMed ID: 18839029
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules.
    Caraglia M; Santini D; Bronte G; Rizzo S; Sortino G; Rini GB; Di Fede G; Russo A
    Curr Drug Metab; 2011 Dec; 12(10):944-55. PubMed ID: 21787268
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Memories of John N. Brady: scientist, mentor and friend.
    Pise-Masison CA; Marriott SJ
    Retrovirology; 2009 May; 6():48. PubMed ID: 19454030
    [TBL] [Abstract][Full Text] [Related]  

  • 60. First person profile: James Armitage, MD: This oncology trailblazer describes his life and career as more fun than he deserved. For colleagues, however, he is an ongoing source of inspiration.
    Printz C
    Cancer; 2019 Feb; 125(3):329-330. PubMed ID: 30665268
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.